(Q39557202)

13 September 2017

title

Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis (English)

1 reference

13 September 2017

Victoria Makovski

1

1 reference

13 September 2017

Roni Haklai

series ordinal

2

1 reference

13 September 2017

Yoel Kloog

series ordinal

3

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 August 2011

1 reference

International Journal of Cancer

13 September 2017

published in

1 reference

13 September 2017

volume

130

1 reference

13 September 2017

issue

6

1 reference

13 September 2017

page(s)

1420-1429

1 reference

Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis

13 September 2017

cites work

1 reference

Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges

21 January 2018

1 reference

Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner

21 January 2018

1 reference

The Rheb family of GTP-binding proteins

21 January 2018

1 reference

Localization of Rheb to the endomembrane is critical for its signaling function

21 January 2018

1 reference

Ras proteins: different signals from different locations

21 January 2018

1 reference

Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.

21 January 2018

1 reference

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

Dislodgment and accelerated degradation of Ras.

21 January 2018

1 reference

New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models

21 January 2018

1 reference

Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)

21 January 2018

1 reference

Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras.

21 January 2018

1 reference

Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy

21 January 2018

1 reference

Measuring Ras-family GTP levels in vivo--running hot and cold

21 January 2018

1 reference

A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration

21 January 2018

1 reference

Uterine leiomyoma in the Eker rat: a unique model for important diseases of women.

21 January 2018

1 reference

Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent

21 January 2018

1 reference

Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid

21 January 2018

1 reference

Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin

21 January 2018

1 reference

Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration

21 January 2018

1 reference

The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord.

21 January 2018

1 reference

Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration

21 January 2018

1 reference

Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice

21 January 2018

1 reference

Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling

21 January 2018

1 reference

RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation

21 January 2018

1 reference

Therapeutic targeting of mTOR in tuberous sclerosis

21 January 2018

1 reference

Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid

21 January 2018

1 reference

Ras family signaling: therapeutic targeting

21 January 2018

1 reference

Ras plasma membrane signalling platforms

21 January 2018

1 reference

The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer

21 January 2018

1 reference

Galectin-1 Augments Ras Activation and Diverts Ras Signals to Raf-1 at the Expense of Phosphoinositide 3-Kinase

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.26139

1 reference

13 September 2017

1 reference